Pfizer PFE Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value

Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value at other companies

Willis Towers WatsonWTW

$18M—

General MillsGIS

$0—

American International GroupAIG

-$17M-113%

Raymond James FinancialRJF

1%0.0pp

KKR & Co.KKR

$0—

Apollo Global ManagementAPO

$617M-18.0%

Other financials

Income statement

See full

Revenue$14.5B+5.4%

Gross profit$10.9B+0.3%

Net income$2.7B-9.4%

EPS (diluted)$0.47-9.6%

Balance sheet

See full

Cash & equivalents$1.8B+18.8%

Total debt$64.4B+5.0%

Total equity$90.1B-0.3%

Total assets$207.62B-0.2%

Cash flow

See full

Operating cash flow$2.6B+12.0%

CapEx$436.0M-22.7%

Free cash flow$2.2B+23.0%

Valuation

See full

Market cap$143.68B+11.1%

Enterprise value$206.35B+9.2%

P/E11.9×—

P/S2.3×+0.2×

Profitability

See full

Gross margin73.5%+1.2pp

Net margin15.7%—

Returns & leverage

See full

Return on equity10.6%—

Debt / equity0.7×0.0×

Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue.

The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pfizer's fair value, measurement with unobservable inputs reconciliation, recurring basis, liability value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Pfizer's fair value, measurement with unobservable inputs reconciliation, recurring basis, liability value?: Pfizer (PFE) reported fair value, measurement with unobservable inputs reconciliation, recurring basis, liability value of $2.04B in Q1 2026.